Literature DB >> 28275265

Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Leendert A Trouw1, Theo Rispens2, Rene E M Toes1.   

Abstract

The presence of autoantibodies is one of the hallmarks of rheumatoid arthritis (RA). In the past few decades, rheumatoid factors (autoantibodies that recognize the Fc-tail of immunoglobulins) as well as anti-citrullinated protein antibodies (ACPAs) have been studied intensively. ACPAs recognize post-translationally modified proteins in which the amino acid arginine has been converted into a citrulline. More recently, other autoantibody systems recognizing post-translationally modified proteins have also gained attention, including autoantibodies recognizing fragmented immunoglobulin (anti-hinge antibodies), autoantibodies recognizing acetylated proteins and autoantibodies recognizing proteins that are modified by adducts formed under oxidative stress. In particular, detailed insights have been obtained on the presence and properties of autoantibodies recognizing carbamylated proteins, commonly called anti-carbamylated protein (anti-CarP) antibodies. In this Review, we summarize the current knowledge relating to these emerging autoantibodies that recognize post-translationally modified proteins identified in RA, with an emphasis on anti-CarP antibodies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275265     DOI: 10.1038/nrrheum.2017.15

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  107 in total

1.  Behavior of the rheumatoid arthritis agglutinating factor with immune precipitates.

Authors:  J H VAUGHAN
Journal:  J Immunol       Date:  1956-09       Impact factor: 5.422

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  Anti-carbamylated protein antibodies in patients with ageing associated inflammatory chronic disorders.

Authors:  Marcos López-Hoyos; Lorena Álvarez-Rodríguez; Michael Mahler; Silvia Torices; Jaime Calvo-Alén; Ignacio Villa; Andrea Seaman; Alvin Yee; Victor Martínez-Taboada
Journal:  Rheumatology (Oxford)       Date:  2015-11-27       Impact factor: 7.580

Review 4.  Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis.

Authors:  Stéphane Jaisson; Christine Pietrement; Philippe Gillery
Journal:  Clin Chem       Date:  2011-07-18       Impact factor: 8.327

Review 5.  Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease.

Authors:  Derrick T Antoniak; Michael J Duryee; Ted R Mikuls; Geoffrey M Thiele; Daniel R Anderson
Journal:  Free Radic Biol Med       Date:  2015-11-04       Impact factor: 7.376

6.  Homocitrulline as marker of protein carbamylation in hemodialyzed patients.

Authors:  Stéphane Jaisson; Isabelle Kazes; Aurore Desmons; Fouad Fadel; Jean-Baptiste Oudart; Izabella C R Dos Santos-Weiss; Hervé Millart; Fatouma Touré; Philippe Rieu; Philippe Gillery
Journal:  Clin Chim Acta       Date:  2016-06-11       Impact factor: 3.786

7.  Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.

Authors:  Anita N Kremer; Judith C van der Griendt; Edith D van der Meijden; M Willy Honders; Burcu Ayoglu; Jochen M Schwenk; Peter Nilsson; J H Frederik Falkenburg; Marieke Griffioen
Journal:  Haematologica       Date:  2013-10-04       Impact factor: 9.941

8.  MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis.

Authors:  I Tchetverikov; H K Ronday; B Van El; G H Kiers; N Verzijl; J M TeKoppele; T W J Huizinga; J DeGroot; R Hanemaaijer
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

9.  Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.

Authors:  Anouk L Feitsma; Ellen I H van der Voort; Kees L M C Franken; Hanane el Bannoudi; Berendina G Elferink; Jan W Drijfhout; Tom W J Huizinga; René R P de Vries; René E M Toes; A Ioan-Facsinay
Journal:  Arthritis Rheum       Date:  2010-01

10.  Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.

Authors:  H Koppejan; L A Trouw; J Sokolove; L J Lahey; T J W Huizinga; I A Smolik; D B Robinson; H S El-Gabalawy; R E M Toes; C A Hitchon
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

View more
  44 in total

1.  The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis.

Authors:  Yi Tian Ting; Jan Petersen; Sri H Ramarathinam; Stephen W Scally; Khai L Loh; Ranjeny Thomas; Anish Suri; Daniel G Baker; Anthony W Purcell; Hugh H Reid; Jamie Rossjohn
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

Review 2.  The case for periodontitis in the pathogenesis of rheumatoid arthritis.

Authors:  Jan Potempa; Piotr Mydel; Joanna Koziel
Journal:  Nat Rev Rheumatol       Date:  2017-08-24       Impact factor: 20.543

3.  The Benefits of Complement Measurements for the Clinical Practice.

Authors:  Anne Grunenwald; Lubka T Roumenina
Journal:  Methods Mol Biol       Date:  2021

Review 4.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

5.  Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis.

Authors:  Keito Hoshitsuki; Sanjay Rathod; Manda J Ramsey; Lei Zhu; Larry W Moreland; Christian A Fernandez
Journal:  J Pharmacol Exp Ther       Date:  2020-10-02       Impact factor: 4.030

6.  Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of normal human B cells.

Authors:  Tao Huang; Mary Mathieu; Sophia Lee; Xinhua Wang; Yee Seir Kee; Jack J Bevers; Claudio Ciferri; Alberto Estavez; Manda Wong; Nancy Y Chiang; Gerald Nakamura; Randall J Brezski
Journal:  J Biol Chem       Date:  2017-11-30       Impact factor: 5.157

Review 7.  The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

Review 8.  Biological classification of childhood arthritis: roadmap to a molecular nomenclature.

Authors:  Peter A Nigrovic; Robert A Colbert; V Michael Holers; Seza Ozen; Nicolino Ruperto; Susan D Thompson; Lucy R Wedderburn; Rae S M Yeung; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2021-03-17       Impact factor: 20.543

Review 9.  Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives.

Authors:  Johan Rönnelid; Carl Turesson; Alf Kastbom
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 10.  Redox-Mediated Carbamylation As a Hapten Model Applied to the Origin of Antibodies to Modified Proteins in Rheumatoid Arthritis.

Authors:  Maria Isabel Trejo-Zambrano; Eduardo Gómez-Bañuelos; Felipe Andrade
Journal:  Antioxid Redox Signal       Date:  2021-06-04       Impact factor: 7.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.